Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Anidulafungin

FDA-approved product (powder, intravenous), marketed as Eraxis.

Registered studies
43
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Anidulafungin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Candidemia
  • Candidiasis
  • Peritonitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antimycotics for systemic use
FDA pharmacologic class
Echinocandin Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX06; FDA class Echinocandin Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

43registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Anidulafungin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Anidulafungin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia

    NCT06907992 · start 2025-05-01

    Registered record
    Registry ID
    NCT06907992
    Conditions
    Candidemia
    Interventions
    Antifungal treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-05-01
    Completion
    2027-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidemia
    InterventionAntifungal treatment
    PhaseNot recorded
    Registry statusNot yet recruiting

  • A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

    NCT05178862 · start 2022-08-03

    Registered record
    Registry ID
    NCT05178862
    Conditions
    Candidiasis, Invasive; Candidemia
    Interventions
    SCY-078; Fluconazole; Echinocandin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2022-08-03
    Completion
    2025-12-16
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis, Invasive; Candidemia
    InterventionSCY-078; Fluconazole; Echinocandin
    PhasePhase 3
    Registry statusTerminated

  • Translational PKPD Modeling of Anti-infective Drugs Used in Pediatric Units.

    NCT05426499 · start 2021-10-01

    Registered record
    Registry ID
    NCT05426499
    Conditions
    Population Modeling of Anti-infective Drugs
    Interventions
    Patients requiring cefotaxime treatment; Patients requiring meropenem treatment; Patients requiring fluconazole treatment; Patients requiring isavuconazole treatment; Patients requiring anidulafungin treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-10-01
    Completion
    2025-09-30
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPopulation Modeling of Anti-infective Drugs
    InterventionPatients requiring cefotaxime treatment; Patients requiring meropenem treatment; Patients requiring fluconazole treatment; Patients requiring isavuconazole treatment +1 more
    PhaseNot recorded
    Registry statusUnknown

  • Azole-echinocandin Combination Therapy for Invasive Aspergillosis

    NCT04876716 · start 2021-05-11

    Registered record
    Registry ID
    NCT04876716
    Conditions
    Invasive Aspergillosis
    Interventions
    Azole; Anidulafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-05-11
    Completion
    2024-05-01
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Aspergillosis
    InterventionAzole; Anidulafungin
    PhasePhase 3
    Registry statusTerminated

  • Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT)

    NCT02021123 · start 2014-08

    Registered record
    Registry ID
    NCT02021123
    Conditions
    Obesity Morbid
    Interventions
    Anidulafungin 100mg single dose iv
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-08
    Completion
    2014-10
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity Morbid
    InterventionAnidulafungin 100mg single dose iv
    PhasePhase 4
    Registry statusCompleted

  • Negative Beta Glucan in ICU Patients

    NCT01734525 · start 2012-11

    Registered record
    Registry ID
    NCT01734525
    Conditions
    Candidemia
    Interventions
    Anidulafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11
    Completion
    2013-12
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidemia
    InterventionAnidulafungin
    PhasePhase 4
    Registry statusCompleted

  • Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents

    NCT01686607 · start 2012-10-01

    Registered record
    Registry ID
    NCT01686607
    Conditions
    Systemic Fungal Infections
    Interventions
    Parenteral micafungin application; Other parenteral antifungal drugs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-10-01
    Completion
    2018-04-30
    Enrolment
    40,110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Fungal Infections
    InterventionParenteral micafungin application; Other parenteral antifungal drugs
    PhaseNot recorded
    Registry statusCompleted

  • Impact of Capillary Leak and Hypoalbuminemia on PK/PD of Anidulafungin and Caspofungin in Critically Ill Patients

    NCT04045366 · start 2012-09-21

    Registered record
    Registry ID
    NCT04045366
    Conditions
    Critically Ill Patients
    Interventions
    Sample collection
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2012-09-21
    Completion
    2025-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritically Ill Patients
    InterventionSample collection
    PhaseNot recorded
    Registry statusUnknown

  • Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

    NCT01188759 · start 2012-05

    Registered record
    Registry ID
    NCT01188759
    Conditions
    Aspergillosis; Invasive Pulmonary Aspergillosis; Neuroaspergillosis
    Interventions
    Voriconazole; Anidulafungin; Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2012-05
    Completion
    2014-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis; Invasive Pulmonary Aspergillosis; Neuroaspergillosis
    InterventionVoriconazole; Anidulafungin; Voriconazole
    PhasePhase 3
    Registry statusWithdrawn

  • Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV

    NCT00802854 · start 2012-03-02

    Registered record
    Registry ID
    NCT00802854
    Conditions
    Candidemia; Other Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-03-02
    Completion
    2016-05-20
    Enrolment
    244

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidemia; Other Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients

    NCT01303549 · start 2011-11

    Registered record
    Registry ID
    NCT01303549
    Conditions
    Liver Disease; Fungal Infection
    Interventions
    Anidulafungin; Liposomal amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-05
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Disease; Fungal Infection
    InterventionAnidulafungin; Liposomal amphotericin B
    PhasePhase 4
    Registry statusCompleted

  • Anidulafungin Pharmacokinetics in Intensive Care Unit Patients

    NCT01438216 · start 2011-09

    Registered record
    Registry ID
    NCT01438216
    Conditions
    Invasive Candidiasis; Candidemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2011-09
    Completion
    2012-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Candidiasis; Candidemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom

    NCT01202253 · start 2011-02

    Registered record
    Registry ID
    NCT01202253
    Conditions
    Candidiasis
    Interventions
    anidulafungin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-02
    Completion
    2011-05
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis
    Interventionanidulafungin
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia

    NCT01270490 · start 2011-01

    Registered record
    Registry ID
    NCT01270490
    Conditions
    Candidemia
    Interventions
    Interferon-gamma, Recombinant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2011-01
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidemia
    InterventionInterferon-gamma, Recombinant
    PhasePhase 3
    Registry statusUnknown

  • Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations

    NCT01307930 · start 2011-01

    Registered record
    Registry ID
    NCT01307930
    Conditions
    Obesity; Mycoses
    Interventions
    Anidulafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-01
    Completion
    2012-11
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Mycoses
    InterventionAnidulafungin
    PhasePhase 4
    Registry statusCompleted